Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.71 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MC4R | P32245 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | MC3R | P41968 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 1/20 | 0.33 |
| ▸ | NNMT | P40261 | 4/20 | 0.31 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.30 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.30 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acipimox SCHEMBL29370131 | 0.83 | HCAR2 (1.00) | HCAR2TSHRKMT2ATDP1LMNA | |
| SCHEMBL12442577 | 0.83 | HCAR2 (0.73) | HCAR2 | |
| Acipimox SCHEMBL48922 | 0.83 | HCAR2 (1.00) | HCAR2TSHRKMT2ATDP1LMNA | |
| Acipimox SCHEMBL6057382 | 0.83 | HCAR2 (1.00) | HCAR2TSHRKMT2ATDP1LMNA | |
| Acipimox SCHEMBL28273592 | 0.81 | HCAR2 (0.96) | HCAR2TSHRKMT2ATDP1LMNA | |
| Acipimox SCHEMBL31290731 | 0.81 | HCAR2 (0.96) | HCAR2TSHRKMT2ATDP1LMNA | |
| Acipimox SCHEMBL28986974 | 0.81 | HCAR2 (0.96) | HCAR2TSHRKMT2ATDP1LMNA | |
| Acipimox SCHEMBL28681646 | 0.81 | HCAR2 (0.96) | HCAR2TSHRKMT2ATDP1LMNA | |
| Acipimox SCHEMBL28690337 | 0.81 | HCAR2 (0.96) | HCAR2TSHRKMT2ATDP1LMNA | |
| SCHEMBL9422317 | 0.81 | HCAR2 (0.65) | HCAR2ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4051245-A | HYPOGLYCEMIC AND HYPOLIPAEMIC ACTIVITY | CARLO ERBA, S.P.A. (IT) | 1977-09-27 | — | — | US | claimed |
| JP-6256320-A | — | — | None | — | — | JP | disclosed |
| US-7153965-B2 | Pharmaceutically acceptable inorganic and organic salts of 5-methylpyrazine-2-carboxylic acid-4-oxide | ISP INVESTMENTS INC. (US) | 2006-12-26 | — | — | US | disclosed |
| US-20050261312-A1 | Pharmaceutically acceptable inorganic and organic salts of 5-methylpyrazine-2-carboxylic acid-4-oxide | ISP INVESTMENTS INC. | 2005-11-24 | — | — | US | disclosed |
| JP-H06256320-A | PYRAZINE 4-OXIDE DERIVATIVE EFFECTIVE FOR MYCOBACTERIUM TUBERCULOSIS | KOEI CHEM CO LTD | 1994-09-13 | — | — | JP | disclosed |
| EP-0088395-B1 | A PROCESS FOR THE PREPARATION OF PYRAZINE DERIVATIVES | FARMITALIA CARLO ERBA S.p.A. (IT) | 1986-07-16 | — | — | EP | disclosed |
| US-4511718-A | Preparation of pyrazine derivatives | FARMITALIA CARLO ERBA S.P.A. (IT) | 1985-04-16 | — | — | US | disclosed |
| EP-0088395-A1 | A process for the preparation of pyrazine derivatives | FARMITALIA CARLO ERBA S.p.A. (IT) | 1983-09-14 | — | — | EP | disclosed |
| US-4051245-A | HYPOGLYCEMIC AND HYPOLIPAEMIC ACTIVITY | CARLO ERBA, S.P.A. (IT) | 1977-09-27 | — | — | US | disclosed |
| US-4002750-A | HYPOGLYCEMIC AND HYPOLIPEMIC AGENTS | CARLO ERBA S.P.A. (IT) | 1977-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261312-A1 | Pharmaceutically acceptable inorganic and organic salts of 5-methylpyrazine-2-carboxylic acid-4-oxide | KDM5A, JMJD6, GRIK5 | HCAR2 372/4885SIRT6 729/4885ADORA3 1175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.